Demographics and patient characteristics
| Characteristic | Cohort 2 (n=296) | Cohort 1 (n=1150) | Cohort 1 H pylori −ve (n=571*) | Cohort 1 H pylori +ve (n=472*) | HELP (n=279) |
|---|---|---|---|---|---|
| *Helicobacter pylori status unknown in 107 patients. | |||||
| †Inclusion criterion. | |||||
| ‡Non-rheumatoid classified as other in this study. | |||||
| OA, osteoarthritis; RA, rheumatoid arthritis; GU, gastric ulcer; DU, duodenal ulcer; NSAIDs, non-steroidal anti-inflammatory drugs; DDD, defined daily dose. | |||||
| Age (y) (mean (SD)) | 57 (13) | 57 (12) | 57 (13) | 57 (11) | 55 (11) |
| Female | 176 (59%) | 751 (65%) | 71% | 61% | 195 (70%) |
| Smokers | 74 (25%) | 261 (23%) | 20% | 25% | 67 (24%) |
| Previous peptic ulcer | 87 (29%) | 328 (29%) | 78% | 82% | 116 (42%) |
| Previous dyspepsia | 256 (86%) | 909 (79%) | 25% | 34% | 138 (49%) |
| H pylori status | |||||
| Unknown | 34 (11%) | 107 (9%) | — | ||
| Negative | 173 (58%) | 571 (50%) | 100% | — | |
| Positive | 89 (30%) | 472 (41%) | 100% | 279 (100%)† | |
| Type of arthritis | |||||
| RA | 128 (43%) | 466 (41%) | 43% | 41% | 116 (42%) |
| OA | 122 (41%) | 471 (41%) | 40% | 39% | — |
| Other | 38 (13%) | 175 (15%) | 14% | 16% | 163 (58%)‡ |
| Combination | 8 (3%) | 38 (3%) | 3% | 3% | — |
| Type of healed lesion | |||||
| None | 150 (51%) | — | — | — | — |
| GU | 62 (21%) | 441 (38%) | 38% | 38% | 35 (13%) |
| GU+DU | 6 (2%) | 40 (3%) | 2% | 5% | 6 (2%) |
| DU | 32 (11%) | 247 (21%) | 17% | 27% | 40 (14%) |
| Erosions only (>11) | 46 (15%) | 422 (37%) | 42% | 29% | NR |
| NSAIDs (DDD) | |||||
| Unspecified* | 44 | 119 | 12% | 9% | |
| 0–1 | 96 (32%) | 456 (39.7%) | 34% | 47% | 59 (21%) |
| >1 | 156 (53%) | 575 (50%) | 54% | 44% | 220 (79%) |
| Steroids | 47 (16%) | 178 (15%) | 38 (14%) | ||